Evaluating the role of a 99mTc-HYNIC-PSMA SPECT scan following a negative bone scan in men with prostate cancer: a single-centre, retrospective cohort study

Main Article Content

CD Oppel
J Lazarus
R Steyn
J Holness

Abstract

Purpose: This study aimed to review the management of patients with high-risk and unfavourable intermediate-risk prostate cancer, who had a 99mTc-HYNIC-PSMA SPECT (technetium-99m hydrazine nicotinamide prostate-specific membrane antigen single-photon emission computerised tomography) scan following a negative 99mTc-MDP (technetium-99m methylene diphosphonate) bone scan.


Materials and methods: This study is a retrospective review of patients with high-risk and unfavourable intermediate-risk prostate cancer, who underwent a 99mTc-PSMA SPECT scan after a negative/equivocal bone scan between January 2018 and December 2020. Patients with a life expectancy of less than 10 years were excluded.


Results: A total of 64 patients were investigated. The mean age was 63 years and the mean prostate-specific antigen (PSA) level was 40 ng/mL. The International Society of Urological Pathology (ISUP) scores were as follows: ISUP 1 in six patients, ISUP 2 in eight patients, ISUP 3 in 13 patients, and ISUP > 4 in 37 patients. A positive 99mTc-PSMA SPECT scan for disease metastases occurred in 20% of the patients who had a negative bone scan. Seven of the patients with a positive 99mTc-PSMA SPECT scan received a bilateral orchiectomy, while four patients received treatment with radical intent. Management of patients with both scans negative included external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) (n = 47), and radical prostatectomy with or without lymph node (LN) dissection (n = 4). A limiting factor was that not every patient underwent conventional cross-sectional imaging of the pelvis and prostate prior to intervention.


Conclusion: A 99mTc-PSMA SPECT scan is a valuable diagnostic tool and was able to identify one in five men (20%) who are understaged by bone scan, allowing for their management plan to be tailored and sparing them morbid intervention.

Article Details

Section
Original Research
Author Biographies

CD Oppel, University of Cape Town

Division of Urology and Department of Nuclear Medicine, Groote Schuur Hospital, University of Cape Town, South Africa

J Lazarus, University of Cape Town

Division of Urology and Department of Nuclear Medicine, Groote Schuur Hospital, University of Cape Town, South Africa

R Steyn, University of Cape Town

Division of Urology and Department of Nuclear Medicine, Groote Schuur Hospital, University of Cape Town, South Africa

J Holness, University of Cape Town

Division of Urology and Department of Nuclear Medicine, Groote Schuur Hospital, University of Cape Town, South Africa